PBLS — Parabilis Medicines, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1657677 ·
Last close
$28.25
Market Cap
$3.49B
52W High
$42.49
52W Low
$22.66
ADV30
1,017,056
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 148,000 | — | -50,886,000 | -52,463,000 | 1,175,262,000 | 1,087,060,000 | 127,528,000 |
| Mar 2026 | 0 | — | -47,453,000 | -45,316,000 | 384,173,000 | 329,039,000 | 139,953,000 |
| Dec 2025 | 0 | — | -40,473,000 | -39,278,000 | 80,820,000 | 27,711,000 | 97,344,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-118,066,000
Investing CF
$-3,232,000
Financing CF
$1,213,757,000
CapEx
$-1,075,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.26
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-639,283,000
Inventory
—
Receivables
—
ST Investments
$33,637,000
EBIT TTM
$-169,618,000
Pretax Income TTM
$-170,915,000
Interest Exp TTM
$1,297,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,262,000
EBITDA
$-190,072,000
Free Cash Flow
—
Enterprise Value
$2,731,282,944
Total Cash
$871,622,976
Total Debt
$41,826,000
Shares Out
123,676,615
Trailing EPS
$-9.76
Book Value
$-168.09
ROE
—
ROA
—
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -152,079,000 | -145,889,000 | 80,820,000 | 97,344,000 | -16,524,000 | -123,713,000 |
| Dec 2024 | 0 | -126,125,000 | -117,914,000 | 149,253,000 | 92,814,000 | 56,439,000 | -103,613,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$1,175,262,000
Forward EPS
$-2.35
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $35.00 · spot: $28.47 · call volume: 14 · put volume: 32
Expected Move to 2027-02-19:
±$8.99
(31.58%) —
implied range
$19.48 –
$37.46
· ATM straddle on $30.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IRON | Disc Medicine, Inc. | $3.49B | $76.57 | — |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.46B | $27.33 | — |
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.54B | $27.52 | — |
| ELVN | Enliven Therapeutics, Inc. | $3.45B | $46.85 | — |
| VKTX | Viking Therapeutics, Inc. | $3.43B | $26.88 | — |
News headlines (Yahoo Finance, 1h cache)
Does Parabilis Medicines (PBLS) Have the Potential to Rally 44.11% as Wall Street Analysts Expect?
2026-11-17 13:55 · Yahoo
Parabilis Medicines: Q3 Earnings Snapshot
2026-11-12 12:38 · Yahoo
Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-12 12:00 · Yahoo
Parabilis Medicines to Participate in Upcoming November Investor Conferences
2026-11-03 12:00 · Yahoo
Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027
2026-10-24 21:02 · Yahoo
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
2026-10-24 12:45 · Yahoo
Parabilis Medicines (PBLS) Stock May Trade At A Premium Despite Fresh Zolucatetide Trial Updates
2026-10-20 20:06 · Yahoo
Parabilis Medicines (PBLS) Could Be 39% Undervalued As Zolucatetide Trial Expands
2026-10-20 19:12 · Yahoo
What Does Parabilis Medicines (PBLS) Expanding Zolucatetide Into FAP Mean?
2026-10-20 18:17 · Yahoo
Parabilis Soars 13% on Upcoming ESMO Data for “First-in-Class” Desmoid Tumor Drug
2026-10-19 17:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.